|Bid||0.00 x 900|
|Ask||7.56 x 4000|
|Day's Range||6.75 - 7.22|
|52 Week Range||4.16 - 20.25|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||24.25|
The initiative is driven by results from an electroCore-HealthyWomen partnered survey, which showed there is a significant lack of awareness of non-drug treatment options for migraine among female patients. According to the survey of over 1,000 female migraine patients between the ages of 18 and 60 years old, 86 percent of patients are completely or somewhat willing to try non-drug treatments, however, only 36 percent expressed awareness of non-drug treatment options. To bridge this knowledge gap surrounding the availability and utility of non-drug treatment options, HealthyWomen and electroCore have developed a suite of content which can be found at HealthyWomen.org/migraine designed to educate women who suffer from migraine and to empower them to initiate a conversation with their HCP about the use of non-drug therapies in their own treatment plan.
LOS ANGELES, CA / ACCESSWIRE / February 1, 2019 / LD Micro is pleased to announce that the LD Micro Index is being reconstituted as of February 1, 2019. Again. We have always held the belief that our industry ...
BASKING RIDGE, N.J., Jan. 28, 2019 -- electroCore, Inc. (“electroCore”) (Nasdaq:ECOR), a commercial-stage bioelectronic medicine company, today announced Chief Executive.
BASKING RIDGE, N.J., Jan. 08, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (ECOR), a commercial-stage bioelectronic medicine company, today announced two clinical studies focused on expanding the use of non-invasive vagus nerve stimulation (nVNS) for the acute and preventive treatment of migraine, and a recent publication of a real-world retrospective analysis which supports the use of nVNS as an effective therapeutic option for patients with cluster headache. “We are committed to expanding our knowledge of the utility of nVNS for the treatment of primary headache disorders. Through the published paper which supports the real-world effectiveness of gammaCore in cluster headache, and the initiation of two important new trials in migraine, we are continually deepening our understanding of the ability of nVNS to address unmet needs among migraine and cluster headache patients,” said Peter S. Staats, M.D., Chief Medical Officer, electroCore.
With the FSS contract, we will deepen our commitment to the underserved patient population diagnosed with migraine or cluster headache, and are one step closer to ensuring patients who may benefit from gammaCore have access to this safe and effective therapy,” said Frank Amato, Chief Executive Officer, electroCore. Designed as a portable, easy-to-use technology, gammaCore can be self-administered by patients as needed, without the potential side effects associated with commonly prescribed drugs.
The direct benefit for electroCore, Inc. (NASDAQ:ECOR), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. However, the trade-off is Read More...
The U.S. FDA plans a major overhaul of how medical devices are regulated and approved in the United States. The changes are intended to keep unsafe products off the market and reward innovation from medical device companies. One medical device ETF has almost tripled the performance of the S&P 500 since its inception.
BASKING RIDGE, N.J., Nov. 27, 2018 (GLOBE NEWSWIRE) -- electroCore, Inc. (“electroCore”) (ECOR), a commercial-stage bioelectronic medicine company, today announced expansion into a new design and development facility to support increasing patient demand of its gammaCore™ non-invasive vagus nerve stimulator product. “We are pleased to announce expansion into this new design, development and manufacturing facility which will ensure we can meet growing patient demand for gammaCore,” said Frank Amato, Chief Executive Officer of electroCore.
If you want to know who really controls electroCore Inc (NASDAQ:ECOR), then you’ll have to look at the makeup of its share registry. Institutions will often hold stock in biggerRead More...